Study Supports MDxHealth's MGMT Methylation Test as Strong Brain Cancer Prognostic
July 13, 2011
Study Supports MDxHealth's MGMT Methylation Test as Strong Brain Cancer Prognostic
A new study provides further support for MDxHealth's PredictMDx brain cancer test, which predicts which patients will respond to the alkylating chemotherapy temozolomide.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDxHealth and Ghent University Begin Collaboration under New Pharmacoepigenomics Center
December 12, 2012 / Pharmacogenomics Reporter - Exact Sciences to Use MDxHealth Methylation Biomarker, PCR Tech in Cologuard Test
January 13, 2011 / PCR Insider - GenomeWeb Feature: The Rise of Lung Cancer Genetic Testing
May 8, 2013 / Pharmacogenomics Reporter - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter - Study Finds Dopamine Gene Variant Predictive of Placebo Response in IBS Patients
October 24, 2012 / Pharmacogenomics Reporter